Agile Therapeutics, Inc. reaffirmed revenue guidance for the Full Year 2023. For the year, the company reaffirmed Net Revenue of At Least $25 Million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3995 USD | +5.27% | +6.53% | -79.51% |
May. 15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
1st Jan change | Capi. | |
---|---|---|
-79.51% | 2.74M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.35% | 22.28B | |
-5.61% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023